ArticleAmerican journal of epidemiology2015
Detectable Symptomatology Preceding the Diagnosis of Pancreatic Cancer and Absolute Risk of Pancreatic Cancer Diagnosis.
Article in American journal of epidemiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Machine Learning Models for Pancreatic Cancer Risk Prediction Using Electronic Health Record Data-A Systematic Review and Assessment.The American journal of gastroenterology · 2024Pooled it
- Using proton pump inhibitors increases the risk of hepato-biliary-pancreatic cancer. A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models.NPJ precision oncology · 2026Article
- Leveraging the Electronic Health Record for Early Detection of Pancreatic Cancer Among 9.4 Million US Veterans.Clinical and translational gastroenterology · 2026Article
- Case Report: Metastatic pancreatic ductal adenocarcinoma initially masked by multiple gastroduodenal ulcers with apparent endoscopic healing: a diagnostic pitfall.Frontiers in medicine · 2026Article
- B-Cell Lymphoma Presenting as a Pancreatic Mass.Journal of medical cases · 2025Article
- Article
- Article
- An Integrative Pancreatic Cancer Risk Prediction Model in the UK Biobank.Biomedicines · 2023Article
- Pancreatic cancer symptom trajectories from Danish registry data and free text in electronic health records.eLife · 2023Article
- Pancreatic cancer is associated with medication changes prior to clinical diagnosis.Nature communications · 2023Article
- Predicting 10-Year Risk of Pancreatic Cancer Using a Combined Genetic and Clinical Model.Gastro hep advances · 2023Article
- Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma.Clinical and translational gastroenterology · 2022Article
- Article
- Prediction of Pancreatic Cancer in Diabetes Patients with Worsening Glycemic Control.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- A Circulating Exosome RNA Signature Is a Potential Diagnostic Marker for Pancreatic Cancer, a Systematic Study.Cancers · 2021Article
- A pooled genome-wide association study identifies pancreatic cancer susceptibility loci on chromosome 19p12 and 19p13.3 in the full-Jewish population.Human genetics · 2021Article
- Early detection of pancreatic cancer.The lancet. Gastroenterology & hepatology · 2020Review
- Association of Glycated Hemoglobin Levels With Risk of Pancreatic Cancer.JAMA network open · 2020Article
- Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Observational
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
The survival duration for pancreatic cancer is short. Given its low lifetime risk (1.5%), established factors for the disease have insufficient specificity to identify individuals at high risk of nonfamilial cancer, and prediagnostic signs and symptoms are vague and not limited to pancreatic causes. We considered whether statistical models that incorporated both risk factors and prediagnosis symptomatology could improve prediction enough to provide practical risk estimates. We combined US Surveillance Epidemiology and End Results (SEER) incidence data from 2008 to 2010 with regression models from representative case-control data from Connecticut (2005-2009) to estimate age- and sex-specific 5-year absolute risks of pancreatic cancer diagnosis. Our risk model included current cigarette smoking (adjusted odds ratio (OR) = 3.3, 95% confidence interval (CI): 2.1, 5.0), current use of proton pump-inhibitor antiheartburn medications (OR = 6.2, 95% CI: 1.7, 23), recent diagnosis of diabetes mellitus (OR = 4.8, 95% CI: 2.2, 11), recent diagnosis of pancreatitis (OR = 19, 95% CI: 3.1, 120), Jewish ancestry (OR = 1.8, 95% CI: 1.1, 3.1), and ABO blood group other than O (OR = 1.3, 95% CI: 1.0, 1.8). In total, 0.87% of controls with combinations of these factors had estimated 5-year absolute risks greater than 5%, and for some, the risks reached more than 10%. Combining risk factors for pancreatic cancer with detectable prediagnostic symptomatology can allow investigators to begin to identify small segments of the population with risks sufficiently high enough to make screening efforts among them potentially useful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.